(Q24235724)

English

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals (English)

0 references

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Nandi Siegfried

5

0 references

author name string

Lawrence CE Mbuagbaw

1

0 references

James H Irlam

2

0 references

Alicen Spaulding

3

0 references

George W Rutherford

4

0 references

publication date

8 December 2010

0 references

Cochrane Database of Systematic Reviews

0 references

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Imputing missing standard deviations in meta-analyses can provide accurate results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

21 January 2018

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic mechanisms of resistance to NRTI and NNRTI.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004246.PUB3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD004246.PUB3

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24235724&oldid=1582848891"